Quetiapine as combination treatment with citalopram in unipolar depression with prominent somatic symptoms: A randomised, double-blind, placebo-controlled pilot study

Psychiatria Danubina

Volumn 25, Issue 3, 2013, Pages 214-220

  Quante, Arnim ^a   Regen, Francesca ^a   Schindler, Frank ^a,d   Volkmer, Klaus ^a   Severus, Emanuel ^b   Urbanek, Carsten ^a   Luborzewski, Alexander ^a   Roepke, Stefan ^a   Anghelescu, Ion ^a,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c Klinik Dr Fontheim   (Germany)

^d Friedrich von Bodelschwingh Klinik   (Germany)

Author keywords

Antidepressants; Citalopram; Major depression; Quetiapine; Somatic symptoms

Indexed keywords

CITALOPRAM; LORAZEPAM; PLACEBO; QUETIAPINE;

ADD ON THERAPY; ADULT; ANTIDEPRESSANT ACTIVITY; ARTICLE; BECK DEPRESSION INVENTORY; BLOOD PRESSURE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-5; ELECTROCARDIOGRAM; ELECTROENCEPHALOGRAM; FEMALE; HAMILTON SCALE; HEART RATE; HUMAN; LABORATORY TEST; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PILOT STUDY; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; SOMATIZATION; SOMNOLENCE; SYMPTOM CHECKLIST 90;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CITALOPRAM; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; DIBENZOTHIAZEPINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PLACEBOS; PSYCHOPHYSIOLOGIC DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84885230094     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M: Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebocontrolled, double-blind study. J Clin Psychiatry 2009; 70:540-9.
2. Baune BT, Caliskan S, Todder D: Effects of the adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression. Hum Psychopharmacol 2007; 22:1-9.
3. Brosen K, Naranjo CA: Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol 2001; 11:275-283.
4. Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH et al.: A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351-1360.
5. Cookson J, Keck PE, Ketter TA, Macfadden W: Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study. Int Clin Psychopharmacol 2007; 22:93-100.
6. Corruble E, Guelfi JD: Pain complaints in depressed inpatients. Psychopathology 2000; 33:307-309.
7. Dannlowski U, Baune BT, Bockermann I Domschke K, Evers S, Arolt V et al: Adjunctive antidepressant treatment with quetiapine in agitated depression: positive effects on symptom reduction, psychopathology and remission rates. Hum Psychopharmacol 2008; 23:587-93.
8. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L: The Hopkins Symptom Checklist (HSCL). Pharmacopsychiatry 1974; 7:79-110.
9. Dharmshaktu P, Tayal V, Kalra BS: Efficacy of antidepressants as analgesics: a review. J Clin Pharmacol 2012; 52:6-17.
10. Dorée JP, Rosiers J, Lew V et al: Quetiapine augmenttation of treatment-resistant depression: a comparison with lithium. Curr Med Res Opin 2007; 23: 333-341.
11. Fava M: Somatic symptoms, depression, and antidepressant treatment. J Clin Psychiatry 2002; 63: 305-307.
12. First MB, Spitzer RL, Gibbon M, Williams J: Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID-I/P, Version 2.0). Biometrics Research Department, New York State Psychiatric Institute, New York, 1996.
13. Garakani A, Martinez JM, Marcus S, Weaver J, Rickels K, Fava M et al.: A randomized, double-blind, and placebocontrolled trial of quetiapine augmentation of fluoxetine in major depressive disorder. Int Clin Psychopharmacol 2008; 23:269-275.
14. Goldstein JM, Christoph G, Grimm S, Liu JW, Widzowski D, Brecher M. Unique mechanism of action for the antidepressant properties of the atypical antipsychotic quetiapine. Poster NR336. APA, San Diego, CA, 2007.
15. Kang EH, Lee IS, Chung SK, Lee SY, Kim EJ, Hong JP et al.: Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: a randomized, open-labeled trial. Psychiatry Res 2009; 169:118-23.
16. Karp JF, Scott J, Houck P Reynolds CF 3rd, Kupfer DJ, Frank E: Pain predicts longer time to remission during treatment of recurrent depression. J Clin Psychiatry 2005; 66:591-597.
17. Leweke FM, Gerth CW, Koethe D, Nolden BM, Klosterkotter J: Efficacy and tolerability of quetiapine in hospitalised schizophrenic patients during the acute treamtent phase: a PMS study. Fortschr Neurol Psychiatr 2007; 75:211-219.
18. Lin CH, Lane HY, Chen CC, Juo SH, Yen CF: Predictors of fluoxetine remission for hospitalized patients with major depressive disorder. Psychiatry Clin Neurosci 2011; 65:510-517.
19. Lindgjaerde O, Ahlfors VG, Beck P, Dencker SJ, Elgen K: The UKU side effect rating scale. Acta Psychiatr Scand. 1987; 384:s85-95.
20. McIntyre A, Gendron A, McIntyre A: Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebocontrolled pilot study. Depress Anxiety 2007; 24:487-494.
21. Millan MJ: Descending control of pain. Prog Neurobiol 2002; 66:355-474.
22. Perahia DG, Quail D, Desaiah D, Montejo AL, Schatzberg AF: Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression. J Psychiatr Res 2009; 43:512-518.
23. Salerno SM, Browning R, Jackson JL: The effect of antidepressant treatment on chronic back pain: a metaanalysis. Arch Intern Med 2002; 162:19-24.
24. Schmitz N, Hartkamp N, Kiuse J, Franke GH, Reister G, Tress W: The Symptom Check-List-90-R (SCL-90-R): a German validation study. Qual Life Res 2000; 9:185-193.
25. Skljarevski V, Ossanna M, Liu-Seifert H, Zhang Q, Chappell A, Iyengar S et al.: A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. Eur J Neurol 2009; 16:1041-8.
26. Smith MA, McCoy R, Hamer-Maansson J, Brecher M: Rapid dose escalation with quetiapine. A pilot study. J Clin Psychopharmacol 2005; 25:331-335.
27. Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A et al.: Efficacy of quetiapine monotherapy in bipolar I and II depression. A double-blind, placebo-controlled study (BOLDER II study). J Clin Psychopharmacol 2006; 26:600-609.
28. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR: The STAR, D Project results: a comprehensive review of findings. Curr Psychiatry Rep 2007; 9:449-59.